講演・口頭発表等 - 朝比奈　靖浩

1. Mina Nakagawa, Miyako Murakawa, Masato Miyoshi, Shun Kaneko, Tsuchiya Jun, Taro Shimizu, Keiya Watakabe, Sei Kakinuma, Ryuichi Okamoto and Yasuhiro Asahina. High GGT levels is a risk factor for HCC development having potential to reflect mitochondrial dysfunction after HCV eradication. AASLD2024 2024.11.15

2. Mina Nakagawa, Miyako Murakawa, Yasuhiro Asahina. Risk factors for HCC and prognosis after SVR to construct an effective post-treatment surveillance system. JDDW2024 2024.11.01

3. Mina Nakagawa, Miyako Murakawa, Masato Miyoshi, Shun Kaneko, Fukiko Kawai-Kitahata, Sayuri Nitta, Sei Kakinuma, Ryuichi Okamoto and Yasuhiro Asahina. SVR後の肝癌、生存とメタボ因子に関する解析. APASL 2024 Kyoto 2024.03.28

4. Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Ryuichi Okamoto. Liver stiffness stratify the disease progression and hepatocellular carcinoma predictive risk score on chronic hepatitis B patients. JDDW2023 2023.11.03 Kobe_Japan

5. Mina Nakagawa, Miyako Murakawa, Masato Miyoshi, Shun Kaneko, Fukiko Kawai-Kitahata, Sayuri Nitta, Sei Kakinuma, Yasuhiro Asahina, Ryuichi Okamoto. Factors associated with HCC development and patients’ survival in patients with an SVR. The 3rd JSH International Liver Conference 2023.09.07

6. Yasuhiro Asahina. HCC development and surveillance after SVR. JDDW 2022, JSH-AASLD joint symposium 2022.10.27

7. Mina Nakagawa, Masato Miyoshi, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Yasuhiro Asahina. Factors associated with HCC development and patients’ survival in patients with an SVR. JSH International Liver Conference 2021 2021.10.03

8. Fukiko Kawai-Kitahata, Yasuhiro Asahina , Sei Kakinuma, Miyako Murakawa, Sayuri Nitta, Masato Miyoshi, Ayako Sato, Jun Tsuchiya, Taro Shimizu, Eiko Takeichi, Mina Nakagawa, Yasuhiro Itsui, Seishin Azuma, Shinji Tanaka , Minoru Tanabe, Shinya Maekawa, Nobuyuki Enomoto and Mamoru Watanabe. Comprehensive analysis of cancer-related genes and aav/hepatitis b virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis b virus infection. EASL The Digital International Liver Congress 2020 2020.08.28 Web開催

9. Yasuhiro Asahina. Do DAA therapy result in an increased risk of hepatocarcinogenesis?. Asian Pacific Digestive Week 2019 2019.12.13 Kolata（India）

10. Yasuhiro Asahina, Fukiko Kawai-Kitahata, Miyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Sei Kakinuma. Comprehensive analysis of cancer gene mutations and viral integration in hepatocellular carcinoma arising from non-fibrotic liver. AASLD The Liver Meeting 2019 2019.11.10 Boston（USA）

11. Yasuhiro Asahina. Prevention and Risk for Liver Cancer after Anti-Viral Therapy in Patients with HBV/HCV. JSH International Liver Conference 2019.10.02 Osaka（Japan）

12. Miyako Murakawa, Yasuhiro Asahina, Emi Inoue, Mina Nakagawa, Jun Tuchiya, Ayako Sato, Masato Miyoshi, Tomoyuki Tsunoda, Fukiko Kitahata-Kawai, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Mamoru Watanabe. The association of serum IFN-lambda 3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents . EASL, The International Liver Congress 2019 2019.04.13 Vienna （Austria）

13. MIna Nakagawa, Yasuhiro Asahina, Jun Tsuchiya, Ayako Sato, Tomoyuki Tsunoda, Msato Miyosh, Emi Inoue, Fukiko Kawai-Kitahata, MIyako Murakawa, Sayuri Nitta, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Makoto Tomita, Mamoru Watanabe. Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients. EASL, The International Liver Congress 2019 2019.04.13 Messe Wien Congress and Exhibition Center(Vienna （Austria）)

14. Asahina Y. Increased risk of HCC following DAA: fact or fiction? / Follow up strategy after SVR in chronic hepatitis C. Asian Pacific Digestive Week 2018 2018.11.16 Seoul（Korea）

15. Nitta S, Kato T, Tuchiya J, Sato A, Tsunoda T, Miyoshi M, Inoue- Shinomiya E, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Asahina Y. The Characteristic and the Anti-HCV Reagents Susceptibility Analysis of NS5A Resistance-Associated Substitutions (RAS) Detected after Daa Treatment Failure Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA）

16. Nakagawa M, Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tomita M, Watanabe M.. Post-Treatment M2BPGi Level Is Useful for Predicting HCC Occurrence and Recurrence after Viral Eradication in Chronic Hepatitis C Patients. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco (USA）

17. Asahina Y, Kawai-Kitahata F, Murakawa M, Nitta S, Nakagawa M, Kakinuma S, Watanabe M. Gene Mutational Profile and Viral Integration in Hepatocellular Carcinoma with or without HBV/HCV Suppression. AASLD, The Liver Meeting 2018 2018.11.10 San Francisco（USA）

18. Nitta S, Kato T, Tuchiya J, Shinomiya-Inoue E, Sato A, Tsunoda T, Miyoshi M, Kitahata-Kawai F, Murakawa M, Istui Y, Azuma S, Nakagawa M, Kakinuma S, Asahina Y. The in vitro analysis of NS5A resistance-associated substitutions (RAS) observed in DAA treatment failure patients. 25th International Symposium on Hepatitis C Virus and Related Viruses 2018.10.09 Dublin（Ireland）

19. Asahina Y, Kakinuma S . HBV reactivation and changes in interferon-stimulated gene expression during treatment of direct-acting antivirals for HCV: Analyses in a novel in vitro model for HBV-HCV coinfection using human induced pluripotent stem cell-derived hepatic cells . EASL, The International Liver Congress 2018 2018.04.14 Paris（France）

20. Kitahata-Kawai F, Asahina Y. Difference of gene mutational profile among viral- and non-viral HCC with or without prior HBV infection: Results of comprehensive deep sequencing analyses of cancer genes and HBV/A AV integration. . EASL, The International Liver Congress 2018 2018.04.14 Paris(France)